A detailed history of Ra Capital Management, L.P. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 1,000,000 shares of AXSM stock, worth $97.8 Million. This represents 1.25% of its overall portfolio holdings.

Number of Shares
1,000,000
Previous 1,000,000 -0.0%
Holding current value
$97.8 Million
Previous $80.5 Million 11.61%
% of portfolio
1.25%
Previous 1.21%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$65.72 - $80.5 $65.7 Million - $80.5 Million
1,000,000 New
1,000,000 $80.5 Million
Q4 2023

Feb 14, 2024

BUY
$57.42 - $83.61 $57.4 Million - $83.6 Million
1,000,000 New
1,000,000 $79.6 Million
Q2 2023

Aug 14, 2023

BUY
$58.41 - $90.35 $58.4 Million - $90.4 Million
1,000,000 New
1,000,000 $71.9 Million
Q3 2021

Nov 15, 2021

SELL
$19.91 - $68.26 $33 Million - $113 Million
-1,655,447 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$66.31 - $86.52 $25.2 Million - $32.9 Million
-379,685 Reduced 18.66%
1,655,447 $135 Million
Q2 2020

Aug 14, 2020

BUY
$49.87 - $98.69 $6.53 Million - $12.9 Million
131,038 Added 6.88%
2,035,132 $167 Million
Q1 2020

May 15, 2020

BUY
$41.2 - $101.31 $63.3 Million - $156 Million
1,536,278 Added 417.68%
1,904,094 $112 Million
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $4.96 Million - $31.5 Million
-296,569 Reduced 44.64%
367,816 $38 Million
Q3 2019

Nov 14, 2019

SELL
$20.24 - $29.16 $13.7 Million - $19.7 Million
-676,443 Reduced 50.45%
664,385 $13.4 Million
Q2 2019

Aug 14, 2019

SELL
$13.46 - $25.75 $26.3 Million - $50.3 Million
-1,952,961 Reduced 59.29%
1,340,828 $34.5 Million
Q1 2019

May 15, 2019

BUY
$2.63 - $16.34 $8.66 Million - $53.8 Million
3,293,789 New
3,293,789 $46.9 Million

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $4.19B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.